Evaluating the Risks of Puberty Blockers: A Call for FDA Accountability

This chapter explores the FDA's role in regulating puberty blockers, focusing on concerns over insufficient warnings about serious side effects like brain swelling and vision loss. It highlights the lack of long-term safety data and raises questions about the influence of external pressures on the FDA's transparency regarding drug safety.